Overview
PT-141 (bremelanotide) is a melanocortin receptor agonist investigated in neurogenic pathway research.
Mechanism of action
Selective activity at MC4R, central to research on arousal signaling.
Research summary
Clinical research literature exists for related indications; supplied here strictly for laboratory research.
Research applications
- Sexual-response and arousal research
- Melanocortin CNS-pathway studies
- Behavioural neuroscience investigation
Typical research dosing
| Period | Dose | Units (U-100) |
|---|---|---|
| Research protocol | 0.5–2 mg | — |
Reconstitution & storage
Reconstitute with 2 mL bacteriostatic water for 10 mg vial.
Safety
Research use only.
References
- Kingsberg SA et al. Obstet Gynecol 2019;134:899-908
For research use only. Not for human or veterinary consumption. Not FDA-approved for the treatment or prevention of any disease.